Compare RWT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | AKBA |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.8M | 729.1M |
| IPO Year | 1995 | 2014 |
| Metric | RWT | AKBA |
|---|---|---|
| Price | $5.82 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $6.86 | $6.25 |
| AVG Volume (30 Days) | 1.4M | ★ 3.0M |
| Earning Date | 02-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 12.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $120,897,000.00 | ★ $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | $46.22 | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $4.68 | $1.30 |
| 52 Week High | $6.73 | $4.08 |
| Indicator | RWT | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 38.09 |
| Support Level | $5.63 | $1.30 |
| Resistance Level | $6.00 | $1.41 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 72.79 | 24.48 |
Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.